Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

Simple Summary The tumor mutational burden (TMB) can be defined as the number of
somatic mutations per megabase of the sequenced genome. It correlates with tumor …

Although the incidence of endometrial carcinoma (EC) is similar in Black and White women,
racial disparities are stark, with the highest mortality rates observed among Black patients …

Cancer genomes from patients with African (AFR) ancestry have been poorly studied in
clinical research. We leverage two large genomic cohorts to investigate the relationship …

Background Advanced penile squamous cell carcinoma (pSCC) is a rare and aggressive
malignancy with limited success of immune‐checkpoint inhibitors (ICIs). Approximately half …

Cancer is a genomic disease in that gene alterations drive the cellular growth and immune
surveillance perturbations that enable malignant cells to take hold and to metastasize …

Artificial intelligence (AI) in oncology is advancing beyond algorithm development to
integration into clinical practice. This review describes the current state of the field, with a …

Background Tumor mutation burden (TMB) is an important biomarker to predict response to
anti-PD-L1 treatment across cancer types. TruSight Oncology 500 (TSO500) is currently …

The field of cancer neoantigen investigation has developed swiftly in the past decade.
Predicting novel and true neoantigens derived from large multi-omics data became difficult …

Advances in molecular diagnostics have enabled the identification of targetable driver
pathogenic variants, forming the basis of precision oncology care. However, the adoption of …